Table 1.
Neutralizing potency of coronavirus disease 2019 (COVID‐19) vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron (B.1.1.529) variant
| Authors | Primary vaccination | Booster vaccine dose | |||
|---|---|---|---|---|---|
| Vaccines; sample collection | Neutralization assay | Reduced Omicron neutralization (folds) | Vaccines; sample collection | Increased Omicron neutralization after booster (folds) compared to pre‐booster | |
| Dejnirattisai W et al. (2021) 3 | 2 × ChAdOx1 or 2 × BNT162b2; ~28 days | Live virus neutralization assay | Vs. ancestral strain: ChAdOx1: ↓ × 13.3; BNT162b2: ↓ × 29.8 | No | ‐ |
| Vs. delta variant: ChAdOx1: ↓ × 5.2; BNT162b2: ↓ × 25.1 | |||||
| Ai J et al. (2021) 4 | 2 × BBIBP‐CorV; ~14 days | Pseudotyped virus neutralization assay | Vs. ancestral strain: BBIBP‐CorV: ↓ × 11.6; | 1 × BBIBP‐CorV; 14−28 days | BBIBP‐CorV: ↑ × 9.6 |
| Vs. delta variant: BBIBP‐CorV: ↓ × 7.9 | |||||
| Garcia‐Beltran WF et al. (2021) 5 | 2 × BNT162b2 or 2 × mRNA‐1273; <3 months | Pseudotyped virus neutralization assay | Vs. ancestral strain: BNT162b2: ↓ × 43; mRNA‐1273: ↓ × 122 | 1 × BNT162b2 or 1 × mRNA‐1273; <3 months | BNT162b2 ↑ × 27; mRNA‐1273: ↑ × 19 |
| Doria‐Rose NA et al. (2021) 6 | 2 × mRNA‐1273; ~14 days | Pseudotyped virus neutralization assay | Vs. ancestral strain: mRNA‐1273: ↓ × 8.9 | 1 × mRNA‐1273; 14 days | mRNA‐1273: ↑ × 12.6 |
| Schmidt F et al. (2021) 7 | 2 × BNT162b2 or 1 × Ad26.COV2.S; ~1.3 month | Pseudotyped virus neutralization assay | Vs. ancestral strain: BNT162b2: ↓ × 127; Ad26.COV2.S: No neutralization | 1 × BNT162b2 or 1 × Ad26.COV2.S; ~30 days | BNT162b2: ↑ × 42.1; Ad26.COV2.S: unavailable |
| Cameroni E et al. (2021) 8 | 2 × BNT162b2 or 2 × mRNA‐1273 or 2 × ChAdOx1 or 1 × Ad26.COV2.S; 2 × Sinovac; 2 × Sptunik; 14−28 days | Pseudotyped virus neutralization assay | Vs. ancestral strain: BNT162b2: ↓ × 44; mRNA‐1273: ↓ × 33; ChAdOx1: ↓× 36; Ad26.COV2.S: No neutralization; Sinovac: No neutralization; Sptunik: No neutralization | No | ‐ |
| Lu L et al. (2021) 9 | 2 × BNT162b2 or 2 × Sinovac; ~1 month | Live virus neutralization assay | Vs. ancestral strain: BNT162b2: ↓ × 38.7; Sinovac ↓ × 4.3 | No | ‐ |
| Vs. delta variant: BNT162b2: ↓ × 21.0; Sinovac ↓ × 2.1 | |||||
| Cele S et al. (2021) 10 | 2 × BNT162b2; 10−63 days | Live virus neutralization assay | Vs. ancestral strain: BNT162b2: ↓ × 22 | No | ‐ |
| Muik A et al. (2021) 11 | 2 × BNT162b2; ~21 days | Pseudotyped virus neutralization assay | Vs. ancestral strain: BNT162b2: ↓ × 22.8 | 1 × BNT162b2; ~28 days | BNT162b2: ↑ × 23.4 |
| Vs. delta variant: BNT162b2: ↓ × 10.4 | |||||
| Mallory R et al. (2021) 12 | 2 × NVX‐CoV2373; ~14 days | hACE2 receptor‐binding test | Vs. ancestral strain: NVX‐CoV2373: ↓ × 8.2 | 1 × NVX‐CoV2373; ~28 days | NVX‐CoV2373: ↑ × 14.8 |
| Vs. delta variant: NVX‐CoV2373: ↓ × 2.8 | |||||
| Yu X et al. (2021) 13 | 2 × BBIBP‐CorV; ~28 days | Pseudotyped virus neutralization assay | Vs. ancestral strain: BBIBP‐CorV: ↓ × 20.1 | 1 × BBIBP‐CorV; ~28 days | BBIBP‐CorV: ↑ × 3.3 |
| Haveri A et al. (2021) 14 | 2 × BNT162b2; ~21 days | Pseudotyped virus neutralization assay | Vs. ancestral strain: BNT162b2: ↓ × 19.7 | 1 × BNT162b2; ~28 days | BNT162b2: ↑ × 38.4 |
| Gruell H et al. (2021) 15 | 2 × BNT162b2; ~28 days | Pseudotyped virus neutralization assay | Vs. ancestral strain: BNT162b2: ↓ × 68.2 | 1 × BNT162b2; ~21 days | BNT162b2: ↑ × 132.8 |
| Vs. delta variant: BNT162b2: ↓ × 21.5 | |||||
| Nemet I et al. (2021) 16 | 2 × BNT162b2; ~166 days | Live virus neutralization assay | Vs. ancestral strain: BNT162b2: ↓ × 14.9 | 1 × BNT162b2; ~25 days | BNT162b2: ↑ × 96.9 |
| Vs. delta variant: BNT162b2: ↓ × 7.2 | |||||
Note: AstraZeneca ChAdOx1 (adenovirus‐based); Johnson & Johnson Ad26.COV2.S (adenovirus‐based); Moderna mRNA‐1273 (mRNA‐based); Novavax NVX‐CoV2373 (recombinant spike protein vaccine); Pfizer/BioNTech BNT162b2 (mRNA‐based); Sinopharm BBIBP‐CorV (inactivated); Sinovac CoronaVac (inactivated); Sputnik V vaccine (adenovirus‐based).